Details

Autor(en) / Beteiligte

• Horita, Nobuyuki
• Fukuda, Nobuhiko
• Kaneko, Takeshi
• Pircher, Andreas
• Heidegger, Isabel
• Wolf, Dominik
• Herbst, Roy S
• Kuriki, Hiroshi
• Spigel, David R

Titel

Atezolizumab for PD-L1–Selected Patients with NSCLC

Ist Teil von

• The New England journal of medicine, 2021-02, Vol.384 (6), p.583-585

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• To the Editor: In the recent article by Herbst et al. (Oct. 1 issue) 1 regarding a trial of single-agent atezolizumab for first-line treatment of programmed death ligand 1 (PD-L1)–selected patients with non–small-cell lung cancer (NSCLC), Figure 1 did not show specific survival data for patients with intermediate PD-L1 expression (i.e., those with expression on ≥5% of tumor cells or tumor-infiltrating immune cells but not meeting the definition of high expression) or low PD-L1 expression (expression on ≥1% and <5% of tumor cells or tumor-infiltrating cells). Therefore, we have reconstructed the hazard ratios for overall survival in these subgroups from their . . .